Non-Small Cell Lung Cancer Coverage from Every Angle

Recent News

Treatment Duration for Nivolumab in Advanced NSCLC: CheckMate 153
ESMO 2020: Does Immune Oncology Increase the Risk of SARS-CoV2–Related Mortality in NSCLC?
ESMO 2020: Pembrolizumab Versus Docetaxel in Subgroup of Patients With NSCLC
ESMO 2020: Vinorelbine Plus Atezolizumab in Recurrent Stage IV Lung Cancer
ESMO 2020: First-Line Pembrolizumab, Chemotherapy, and Lenvatinib in Metastatic NSCLC
Study Supports Use of RET Inhibitor in RET Fusion–Positive Lung Cancer
ESMO 2020: CNS Recurrence Patterns With Osimertinib in Treatment of NSCLC
ESMO 2020: Is Neoadjuvant Atezolizumab Safe in Patients With Resectable NSCLC?
ESMO 2020: Combining Ipilimumab With PD-1 Blockade in Advanced Lung Cancer
ESMO 2020: Lorlatinib Versus Crizotinib in First-Line Treatment of ALK-Positive NSCLC
ESMO 2020: Is Routine Postoperative Radiotherapy in NSCLC With Mediastinal Nodes of Benefit?
COVID-19 and Lung Cancer: Skin Manifestations With Immunotherapy
Are ‘Light’ Smokers at Increased Risk of Death From Lung Cancer?
FDA Brief: Pemetrexed Injection Receives FDA Approval for Lung Cancer
Pralsetinib Approved by FDA for Metastatic RET Fusion–Positive NSCLC
Survival Outcomes in Lung Cancer in the United Kingdom During the COVID-19 Pandemic
COVID-19 and Thoracic Cancer: First Results From TERAVOLT
Liquid Biopsy Companion Diagnostic Test Approved for Metastatic NSCLC
Lung Cancer and COVID-19: Global Experts Offer Treatment Guidance
Does Nicotine Promote Brain Metastasis of Lung Cancer?
FDA Grants Priority Review for New Durvalumab Dosing Regimen in NSCLC
AACR COVID-19: SRMS Expression in Patients With Lung Cancer
WCLC 2020: Ensartinib Versus Crizotinib in First-Line Treatment of ALK-Positive NSCLC
AACR COVID-19: Changes in Lung Cancer Management
WCLC 2020: Adding Sintilimab to Chemotherapy for Nonsquamous NSCLC
Phase I Trial of Combined MEK and EGFR Inhibition in NSCLC
COVID-19 and Lung Cancer: Proactive Measures for Screening Patients
Osimertinib Given Breakthrough Therapy Designation for EGFR-Mutated Lung Cancer
ctDNA Clearance and Savolitinib Plus Osimertinib in MET-Amplified Lung Cancer
Survival Update With Bevacizumab Plus Erlotinib in Certain Patients With NSCLC
AACR COVID-19: Study Finds Age-Related Differences for Survival
Glucose Transporter Inhibition: Potential Treatment of Certain Lung Cancers
AACR COVID-19: Continuity of Care in Lung Cancer
Adding Platinum Doublet to Immunotherapy Combination in Advanced Lung Cancer
The Gut Microbiome's Response to Immunotherapy for Lung Cancer
Mobile Program Brings Lung Cancer Screening to Patients
Icotinib Dosage May Affect Outcomes in Patients With NSCLC and Genetic Mutation
AACR II: Environmental Factors and Lung Cancer Risk
Screening for Lung Cancer: Draft Recommendation From USPSTF
AACR II: Early-Phase Study of Ensartinib in ALK-Positive NSCLC
Multidisciplinary Care Coordination for Patients With NSCLC
AACR II: Early Results With Dual Inhibitors of IGF and CDK4/6 in Lung Cancer
Interim Results of Trastuzumab Deruxtecan in HER2-Mutated Metastatic NSCLC
AACR II: Flat Dosing of Nivolumab in Patients Previously Treated for NSCLC
HER2-Targeted Therapy With Trastuzumab Deruxtecan in Lung Cancer
AACR II: Potential Link Between Lung Cancer Risk and Sleep Patterns
ASCO20: 3-Year Update on Nivolumab Plus Ipilimumab as First-Line Treatment of NSCLC
ASCO20: Tiragolumab Plus Atezolizumab for PD-L1–Selected NSCLC
ASCO20: Antibody-Drug Conjugate Active in CEACAM5-Expressing Nonsquamous NSCLC
Biologic Therapies for Patient With Both Lung Cancer and Multiple Myeloma
ASCO20: Dual EGFR Tyrosine Kinase Inhibitor Therapy for EGFR-Mutated NSCLC
Frequency of Cardiovascular Events in Patients With Lung Cancer
ASCO20: MET Inhibitor for Lung Cancer With MET Exon 14 Skipping Mutation
Link Between Polypharmacy and Inpatient Hospitalization in Older Patients With Lung Cancer?
ASCO20: Adding Local Stereotactic Radiotherapy to TKI in Oligometastatic Lung Cancer
COVID-19 and Lung Cancer: Should ALK/ROS1 Inhibitor Therapy Be Continued?
ASCO20: Immunotherapy Combination Plus Chemotherapy for Advanced NSCLC
Ramucirumab Plus Erlotinib Approved by FDA in Metastatic NSCLC
ASCO20: High Risk for Hospitalization for Patients With Thoracic Malignancies and COVID-19 Infection
ASCO20: ‘Extraordinary’ Results With Adjuvant Osimertinib in Early-Stage EGFR-Mutant NSCLC
FDA Approves Chemotherapy Plus Immunotherapy Combination in First-Line Treatment of Resistant NSCLC
Pulmonology Expert Panel Offers Guidance During the COVID-19 Pandemic
FDA Approves TKI Inhibitor Brigatinib for ALK-Positive Metastatic NSCLC
COVID-19 Pandemic–Related Challenges in Lung Cancer Therapy
FDA Approves Atezolizumab for Metastatic NSCLC With High PD-L1 Expression
Nivolumab/Ipilimumab Combination Receives FDA Approval in First-Line Treatment of Metastatic NSCLC
ASCO20 Preview: Study Finds Lung Cancer Survival Improved With Even Recent Smoking Cessation
DDW 2020: Risk of Lung Cancer in Patients With Inflammatory Bowel Disease
AACR 2020: Final IMpower150 Analysis of Chemoimmunotherapy in Nonsquamous Lung Cancer
Early Phase of Lung Pathology in COVID-19: Case Studies From China
FDA Approves Selpercatinib for RET Fusion–Positive NSCLC
Capmatinib Approved by FDA for Metastatic MET Exon 14–Mutated NSCLC
AACR 2020: MET Inhibitor Therapy in Lung Cancer With Brain Metastasis
Immunotherapy-Treated Patients With Lung Cancer: Beta-Blocker and Mortality Connection?
AACR 2020: Global Registry of Mortality in Patients With Lung Cancer and COVID-19
Pembrolizumab Receives FDA Accelerated Approval for Alternative Dosing Schedule
AACR 2020: Targeting EGFR Exon 20–Mutant Non–Small Cell Lung Cancer
Lung Cancer Treatment During the COVID-19 Pandemic: Balancing Risks and Benefits

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.